NF-κB and Inflammatory Bone Loss: “Alternative” Family Members Take Their Place at the Table

  • Deborah Novack
  • Chang Yang
  • Jennifer Davis
  • Katherine McCoy
Conference paper

Abstract

NF-κB is a critical signal for osteoclast (OC) differentiation downstream of RANKL, and its disruption blocks bone loss in a variety of disease models in mice. Differently from other TNF family members, RANKL activates both the classical NF-κB pathway, activating p65 and cRel, and the alternative pathway, inducing expression and activation of RelB. Our studies on the role of individual NF-κB subunits have demonstrated that p65 is important for OC precursor survival during a critical period of differentiation but is not necessary for transcription of the OC differentiation program [1]. In contrast, RelB is required for OC differentiation in vitro and for pathological bone loss in vivo [2]. Both deletion and activation of NIK, the upstream kinase regulating RelB activation, significantly modulates osteoclastogenesis, especially in models of inflammatory arthritis. Thus, the alternative NF-κB pathway represents an interesting potential target for the control of bone loss in diseases such as rheumatoid arthritis.

Keywords

Arthritis Osteoporosis Lysozyme Osteocalcin Ligase 

References

  1. 1.
    Vaira S, Alhawagri M, Anwisye I, Kitaura H, Faccio R, Novack DV (2008) RelA/p65 promotes osteoclast differentiation by blocking a RANKL-induced apoptotic JNK pathway in mice. J Clin Invest 118:2088–2097PubMedGoogle Scholar
  2. 2.
    Vaira S, Johnson T, Hirbe AC et al (2008) RelB is the NF-κB subunit downstream of NIK responsible for osteoclast differentiation. Proc Natl Acad Sci USA 105:3897–3902PubMedCrossRefGoogle Scholar
  3. 3.
    Vallabhapurapu S, Matsuzawa A, Zhang W et al (2008) Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-κB signaling. Nat Immunol 9:1364–1370PubMedCrossRefGoogle Scholar
  4. 4.
    Zarnegar BJ, Wang Y, Mahoney DJ et al (2008) Noncanonical NF-κB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat Immunol 9:1371–1378PubMedCrossRefGoogle Scholar
  5. 5.
    Novack DV, Yin L, Hagen-Stapleton A et al (2003) The IκB function of NF-κB2 p100 controls stimulated osteoclastogenesis. J Exp Med 198:771–781PubMedCrossRefGoogle Scholar
  6. 6.
    Aya K, Alhawagri M, Hagen-Stapleton A, Kitaura H, Kanagawa O, Novack DV (2005) NF-κB-inducing kinase controls lymphocyte and osteoclast activities in inflammatory arthritis. J Clin Invest 115:1848–1854PubMedCrossRefGoogle Scholar
  7. 7.
    Liao G, Zhang M, Harhaj EW, Sun SC (2004) Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J Biol Chem 279:26243–26250PubMedCrossRefGoogle Scholar
  8. 8.
    Sasaki Y, Calado DP, Derudder E et al (2008) NIK overexpression amplifies, whereas ablation of its TRAF3-binding domain replaces BAFF:BAFF-R-mediated survival signals in B cells. Proc Natl Acad Sci USA 105:10883–10888PubMedCrossRefGoogle Scholar
  9. 9.
    Yang C, McCoy K, Davis JL et al (2010) NIK stabilization in osteoclasts results in osteoporosis and enhanced inflammatory osteolysis. PLoS One 5:e15383PubMedCrossRefGoogle Scholar
  10. 10.
    Iotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R (1997) Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nat Med 3:1285–1289PubMedCrossRefGoogle Scholar
  11. 11.
    Franzoso G, Carlson L, Xing L et al (1997) Requirement for NF-κB in osteoclast and B-cell development. Genes Dev 11:3482–3496PubMedCrossRefGoogle Scholar

Copyright information

© Springer New York 2013

Authors and Affiliations

  • Deborah Novack
    • 1
  • Chang Yang
    • 1
  • Jennifer Davis
    • 1
  • Katherine McCoy
    • 1
  1. 1.Division of Bone and Mineral Diseases, Departments of Medicine and PathologyWashington University School of MedicineSt. LouisUSA

Personalised recommendations